Valuation: Amplia Therapeutics Limited

Market Cap 6.67Cr 4.68Cr 4.07Cr 3.79Cr 3.48Cr 6.57Cr 447.15Cr 45Cr 18Cr 222.61Cr 18Cr 17Cr 746.45Cr P/E 2027 *
-5.65x
P/E 2028 * -21.7x
Enterprise Value 5.12Cr 3.6Cr 3.13Cr 2.91Cr 2.67Cr 5.04Cr 343.29Cr 34Cr 13Cr 170.9Cr 14Cr 13Cr 573.07Cr EV / Sales 2027 *
-
EV / Sales 2028 * 4.52x
Free-Float
90.48%
Yield 2027 *
-
Yield 2028 * -
1 day+18.58%
1 week-18.18%
1 month-21.74%
3 months-30.77%
6 months-10.00%
Current year+14.07%
1 week 0.08
Extreme 0.0759
0.09
1 month 0.06
Extreme 0.057
0.11
Current year 0.06
Extreme 0.057
0.27
1 year 0.05
Extreme 0.0492
0.27
3 years 0.02
Extreme 0.025
0.27
5 years 0.02
Extreme 0.025
0.27
10 years 0.01
Extreme 0.012
1.6
Manager TitleAgeSince
Chief Executive Officer - 05/12/2022
Director of Finance/CFO - 01/10/2021
Chief Tech/Sci/R&D Officer - 12/05/2025
Director TitleAgeSince
Director/Board Member 70 02/09/2015
Chairman - 25/05/2018
Chairman - 30/06/2026
Change 5-day change 1-year change 3-year change Capi.($)
+18.58%-18.18% - - 4.68Cr
+2.35%+2.74%+38.10%+74.02% 5.65TCr
-2.34%-6.51%+25.66%+62.29% 5.36TCr
-2.44%+1.40%-15.61%-13.72% 2.29TCr
-2.85%-7.78%-9.28%+352.92% 2.14TCr
+0.15%+0.36%+24.28%-14.44% 2.03TCr
-0.01%-2.28%+31.86%-29.13% 1.76TCr
-1.45%-7.15%+17.96%+554.50% 1.47TCr
+3.41%-6.61%+162.81%+287.77% 1.35TCr
-5.25%-4.23%+42.32%+160.72% 1.33TCr
Average +1.73%-3.79%+35.34%+159.44% 2.6TCr
Weighted average by Cap. +0.02%-2.96%+30.18%+120.42%

Financials

2027 *2028 *
Net sales - 1Cr 70.2L 61.02L 56.8L 52.15L 98.47L 67Cr 6.69Cr 2.63Cr 33Cr 2.64Cr 2.58Cr 111.86Cr
Net income -1.16Cr -81.43L -70.78L -65.88L -60.49L -1.14Cr -78Cr -7.77Cr -3.05Cr -39Cr -3.06Cr -2.99Cr -129.76Cr -36L -25.27L -21.97L -20.45L -18.77L -35.45L -24Cr -2.41Cr -94.59L -12Cr -94.9L -92.82L -40Cr
Net Debt -1.55Cr -1.09Cr -94.58L -88.04L -80.83L -1.53Cr -103.86Cr -10Cr -4.07Cr -52Cr -4.09Cr -4Cr -173.38Cr -2.15Cr -1.51Cr -1.31Cr -1.22Cr -1.12Cr -2.12Cr -144.07Cr -14Cr -5.65Cr -72Cr -5.67Cr -5.54Cr -240.5Cr
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
30/26/30 $0.0900 +18.58% 7,360
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1300AUD
Average target price
0.4200AUD
Spread / Average Target
+223.08%

Annual profits - Rate of surprise